Caspofungin: In pediatric patients with fungal infections

Pediatric Drugs

Volumn 11, Issue 4, 2009, Pages 259-269

  Garnock Jones, Karly P ^a,b   Keam, Susan J ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CANDICAS; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN; DEXAMETHASONE; ECHINOCANDIN; EFAVIRENZ; FLUCYTOSINE; ITRACONAZOLE; MYCOPHENOLIC ACID; NELFINAVIR; NEVIRAPINE; PHENYTOIN; POSACONAZOLE; RIFAMPICIN; TACROLIMUS; UNCLASSIFIED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; BRONCHOSPASM; CANDIDIASIS; CHILL; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; HEAT; HUMAN; IN VIVO STUDY; MYCOSIS; NEUTROPENIA; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SWELLING; TACHYCARDIA; VOMITING;

ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; ECHINOCANDINS; HUMANS; INFANT; MYCOSES;

EID: 69749105654     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/00148581-200911040-00005     Document Type: Review

References (43)

1. Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am 2005 Jun; 52 (3): 895-915
2. BlythC, Palasanthiran P, O'Brien TA. Antifungal therapy in childrenwith invasive fungal infections: a systematic review. Pediatrics 2007 Apr 1; 119 (4): 772-784 (Pubitemid 46556677)
3. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009 Mar 1; 48 (5): 503-535
4. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008 Feb 1; 46 (3): 327-360 (Pubitemid 351265310)
5. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 2009; 69 (3): 361-392
6. Keating GM. Posaconazole. Drugs 2005; 65 (11): 1553-1567
7. Merck and Co. Inc. Cancidas® (caspofungin acetate) for injection: US prescribing information [online]. Available from URL: http://www.merck.com/ product/usa/pi-circulars/c/cancidas/cancidas-pi.pdf [Accessed 2009 Jan 21]
8. European Medicies Agency. Cancidas 50 mg powder for concentrate for solution for infusion: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/cancidas/H-379-PI-en.pdf [Accessed 2009 Apr 15]
9. Keating GM, Jarvis B. Caspofungin. Drugs 2001; 61 (8): 1121-1129
10. Keating G, FiggittD.Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs 2003; 63 (20): 2235-2263 (Pubitemid 37289924)
11. McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005; 65 (14): 2049-2068 (Pubitemid 41327370)
12. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: third informational supplement (document M27-S3). Wayne (PA): Clinical and Laboratory Standards Institute, 2008 Apr; 28 (15)
13. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard. Second edition (document M38-A2). Wayne (PA): Clinical and Laboratory Standards Institute, 2008 Apr; 28 (16)
14. Antachopoulos C, Meletiadis J, Sein T, et al. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother 2008 Jan; 52 (1): 321-328
15. Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003 Aug; 41 (8): 3623-3626
16. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008 Jan; 46 (1): 150-156
17. Dannaoui E, Lortholary O, Raoux D, et al. Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006. Antimicrob Agents Chemother 2008 Feb; 52 (2): 778-781
18. Arendrup MC, Fuursted K, Gahrn-Hansen B, et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008 May; 14 (5): 487-494
19. Cuenca-Estrella M, Rodriguez D, Almirante B, et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005 Feb; 55 (2): 194-199
20. González GM, Elizondo M, Ayala J. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. J Clin Microbiol 2008 Sep; 46 (9): 2902-2905
21. Zaoutis TE, Foraker E, McGowan KL, et al. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals. Diagn Microbiol Infect Dis 2005 Aug; 52 (4): 295-298 (Pubitemid 41297566)
22. Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009 Mar; 123 (3): 877-884
23. Posteraro B, Sanguinetti M, Fiori B, et al. Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes. J Antimicrob Chemother 2006 Aug; 58 (2): 458-461 (Pubitemid 44294967)
24. Silver PM, Oliver BG, White TC. Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance. Med Mycol 2008 May; 46 (3): 231-239
25. Geiss H, Dilger S. The post-antifungal effect (PAFE) of caspofungin [abstract no. A-495]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego (CA), 4
26. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000 Apr; 44 (4): 1108-1111
27. Manavathu EK, Ramesh MS, Baskaran I, et al. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004 Feb; 53 (2): 386-389 (Pubitemid 38239980)
28. Flattery A, Hickey E, Gill C, et al. Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis [abstract no. M-1836]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL), 456
29. van de Sande WW, van Vianen W, ten Kate MT, et al. Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2008 Apr; 52 (4): 1345-1350
30. van Vianen W, de Marie S, ten Kate MT, et al. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2006 Apr; 57 (4): 732-740
31. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997 Nov; 41 (11): 2326-2332
32. Hernandez S, López-Ribot JL, Najvar LK, et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained froma patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004 Apr; 48 (4): 1382-1383 (Pubitemid 38405501)
33. Moudgal V, Little T, Boikov D, et al. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005 Feb; 49 (2): 767-769 (Pubitemid 40175691)
34. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008 Aug; 46 (8): 2620-2629
35. Garcia-Effron G, Katiyar SK, Park S, et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008 Jul; 52 (7): 2305-2312
36. Stevens DA, White TC, Perlin DS, et al. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 2005 Mar; 51 (3): 173-178
37. Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 2009 Apr; 53 (4): 1450-1456
38. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005 Nov; 49 (11): 4536-4545
39. Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002 Mar; 46 (3): 739-745
40. Sáez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009 Mar; 53 (3): 869-875
41. Maertens J, Madero L, Reilly A, et al. Arandomized, double-blind, multicenter trial of caspofungin vs. liposomal amphotericin B for empirical antifungal therapy of pediatric patients with persistent fever and neutropenia [abstract no. M-621]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL), 435
42. Cesaro S, Toffolutti T, Messina C, et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol 2004; 73 (1): 50-55 (Pubitemid 38824190)
43. US Food and Drug Administration. Statistical review and evaluation: caspofungin acetate [online]. Available from URL: http://www.fda.gov/cder/foi/ ped-review/2008/021227-caspofungin-statistical-BPCA.pdf [Accessed 2000 Apr 8]